Antibacterial metabolites from an unexplored strain of marine fungi Emericellopsis minima and determination of the probable mode of action against Staphylococcus aureus and methicillin-resistant S. aureus.

Increasing prevalence of drug resistance has led researchers to focus on discovering new antibacterial agents derived from the marine biome. Although ample studies have investigated marine fungi for their bioactive metabolites with hopeful prospects in drug discovery. The present study was aimed to isolate/ identify potential antimethicillin-resistant Staphylococcus aureus compounds producing marine fungal strain from the Indian marine environment. The effective anti-MRSA compound was produced by a marine fungal strain designated as D6. The D6 strain exhibited 99% similarity to Emericellopsis minima based on 18S rRNA gene analysis. The culture conditions of E. minima D6 were optimized using nutritional and environmental parameters for enhanced anti-MRSA compound production. The agar well diffusion assay was used to determine the inhibition zone diameter of the crude extract against S. aureus and methicillin-resistant S. aureus, whereas the broth microdilution method was used to determine their minimum inhibitory concentration (MIC) active fraction. MIC values of the ethyl acetate fraction ranged from 0.8 to 1 mg/mL. SEM analysis revealed that the ethyl acetate fraction induces deep craters in methicillin-resistant S. aureus. Further, GC-MS analysis confirmed the occurrence of a total of 15 major compounds in active ethyl acetate fraction. Some of the major antibacterial compounds included cyclopentanol, isothiazole, benzoic acid, pyrrolo[1,2-a] pyrazine-1,4-dione, and hexahydro. These findings suggest that the marine fungi of E. minima can be a valuable candidate for prospecting antibiotics and an alternative complementary strategy for drug-resistant bacterial infections.